India’s DCGI grants emergency approval to Covishield and Covaxin vaccines

TAGS

In a major step forward in India’s fight against the Covid-19 pandemic, the Drugs Controller General of India (DCGI) has granted emergency use approval to two of the most promising vaccines: Serum Institute of India’s Covishield and Bharat Biotech’s . These vaccines are now set to play a central role in the country’s mass vaccination campaign, which will be crucial in curbing the spread of the virus.

Covishield and Covaxin: India’s first approved Covid-19 vaccines

Covishield, developed by the Serum Institute of India in collaboration with Oxford University and pharmaceutical giant AstraZeneca, has now been granted approval for restricted use by the DCGI. Manufactured in Pune, this vaccine is poised to play a significant role in India’s vaccination efforts. Alongside it, Bharat Biotech’s Covaxin, an indigenous vaccine, has also received the green light for emergency use after presenting comprehensive clinical trial data.

The approval of both vaccines marks a pivotal moment in the ongoing fight against Covid-19, positioning India as one of the first countries to approve vaccines developed by both international and indigenous sources. These vaccines are expected to drastically reduce the impact of the virus, especially in a country that has been severely affected by the pandemic.

See also  Procter & Gamble completes game-changing acquisition of Merck’s consumer health unit

DCGI emphasizes and efficacy

VG Somani, the head of DCGI, affirmed that the approval process for both vaccines had been meticulously conducted, ensuring their safety and efficacy. He reassured the public that both vaccines are “100% safe” and reiterated that the DCGI will never approve a vaccine if there are any concerns about its safety. Somani noted that mild side effects such as fever, pain, or allergy are common with most vaccines, but these reactions are not a cause for concern.

Addressing unfounded claims about the vaccines potentially causing infertility, Somani firmly rejected such rumors, stating that they were baseless and not supported by scientific evidence.

India’s Prime Minister Modi hails the vaccine approvals as a decisive turning point

Prime Minister also weighed in on the vaccine approvals, describing them as a “decisive turning point” in the fight against Covid-19. In a tweet, Modi expressed his congratulations to the scientists and innovators behind the development of Covishield and Covaxin. He emphasized that these approvals would accelerate India’s journey toward becoming a healthier, Covid-free nation.

See also  Kotak Mahindra Bank Q2FY24 results: Standalone PAT surges 24% to Rs 3,191cr

“A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of Serum Institute of India & Bharat Biotech accelerates the road to a healthier & COVID-free nation. Congratulations India. Congratulations to our hardworking scientists & innovators,” Modi tweeted.

The road ahead: Mass vaccination and global impact

With over 10 million confirmed Covid-19 cases and nearly 150,000 deaths, India has been one of the hardest-hit countries in the world. The approval of Covishield and Covaxin comes at a critical time, offering hope for containment and recovery. Both vaccines will now be distributed to millions of individuals, with priority given to healthcare workers and high-risk populations.

India’s vaccination campaign, which will span across urban and rural areas, will be a monumental effort. The government has set ambitious targets to vaccinate millions in the coming months, ensuring that vaccines are accessible to people nationwide.

See also  Krka, Laurus Labs form JV to expand in new markets with focus on India

The approval of these vaccines could also have global implications, as India is a major supplier of vaccines worldwide. The Serum Institute, as one of the largest producers of vaccines, is set to supply millions of doses to other countries, making these vaccines crucial to the global fight against Covid-19.

A new hope in the fight against Covid-19

The of Covishield and Covaxin is a turning point in India’s battle against the Covid-19 pandemic. With millions of doses now ready for distribution, these vaccines are expected to significantly reduce the spread of the virus and help protect the nation’s most vulnerable populations. As India steps into the next phase of the pandemic, the approval of these vaccines brings new hope and a critical tool in the global fight to end Covid-19.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This